Literature DB >> 3125387

The effects of pentobarbital, fentanyl-droperidol, ketamine-xylazine and ketamine-diazepam on arterial blood pH, blood gases, mean arterial blood pressure and heart rate in adult male rats.

S K Wixson1, W J White, H C Hughes, C M Lang, W K Marshall.   

Abstract

Although anesthetics are known to cause respiratory and cardiovascular depression in humans, these adverse effects rarely have been investigated in laboratory rodents. This study evaluated the effects of four different injectable drugs, pentobarbital, fentanyl-droperidol (Innovar-Vet), ketamine-xylazine and ketamine-diazepam on the respiratory and cardiovascular systems of rats. Results showed marked acidosis, hypercarbia and hypoxia with high doses of Innovar-Vet, moderate respiratory depression with all dosages of pentobarbital and minimal respiratory depression with ketamine-xylazine and ketamine-diazepam. Innovar-Vet, ketamine-xylazine and pentobarbital caused profound hypotension, particularly at high dosages, while ketamine-diazepam caused the least depression in mean arterial blood pressure of all drugs evaluated. None of the drugs studied produced significant alterations in heart rate. Throughout all dosages investigated, the ketamine-diazepam combination showed the least overall effects on ventilation and perfusion of the four parenteral drug combinations studied.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3125387

Source DB:  PubMed          Journal:  Lab Anim Sci        ISSN: 0023-6764


  23 in total

1.  Engineering analysis of biological variables: an example of blood pressure over 1 day.

Authors:  W Huang; Z Shen; N E Huang; Y C Fung
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

2.  A fatal response to xylazine and ketamine in a group of rabbits.

Authors:  W P Palmore
Journal:  Vet Res Commun       Date:  1990       Impact factor: 2.459

3.  Evaluation of Analgesic Efficacy of Meloxicam and 2 Formulations of Buprenorphine after Laparotomy in Female Sprague-Dawley Rats.

Authors:  Elizabeth A Nunamaker; Julia L Goldman; Cynthia R Adams; Jeffrey D Fortman
Journal:  J Am Assoc Lab Anim Sci       Date:  2018-08-09       Impact factor: 1.232

4.  Effect of anesthetics on gastric damage using two models of portal hypertension.

Authors:  Paula Rs Câmara; Gisele P Moi; José Geraldo P Ferraz; José Murilo R Zeitune
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-08-06

5.  Captopril improves cerebrovascular structure and function in old hypertensive rats.

Authors:  François Dupuis; Jeffrey Atkinson; Patrick Limiñana; Jean-Marc Chillon
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

6.  Diaphragm muscle activity across respiratory motor behaviors in awake and lightly anesthetized rats.

Authors:  Federico Jimenez-Ruiz; Obaid U Khurram; Wen-Zhi Zhan; Heather M Gransee; Gary C Sieck; Carlos B Mantilla
Journal:  J Appl Physiol (1985)       Date:  2018-01-04

7.  Effect of a short-term fast on ketamine-xylazine anesthesia in rats.

Authors:  Maggie B Struck; Karl A Andrutis; Harvey E Ramirez; August H Battles
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-05       Impact factor: 1.232

8.  High doses of ketamine-xylazine anesthesia reduce cardiac ischemia-reperfusion injury in guinea pigs.

Authors:  Ruben C Sloan; Matthew Rosenbaum; Dorcas O'Rourke; Karen Oppelt; Chad R Frasier; Corinne A Waston; Amanda G Allan; David A Brown
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-05       Impact factor: 1.232

9.  Transient effects of anesthetics on dendritic spines and filopodia in the living mouse cortex.

Authors:  Guang Yang; Paul C Chang; Alex Bekker; Thomas J J Blanck; Wen-Biao Gan
Journal:  Anesthesiology       Date:  2011-10       Impact factor: 7.892

10.  Inhalation of the nerve gas sarin impairs ventilatory responses to hypercapnia and hypoxia in rats.

Authors:  Jianguo Zhuang; Fadi Xu; Matthew J Campen; Cancan Zhang; Juan C Pena-Philippides; Mohan L Sopori
Journal:  Toxicol Appl Pharmacol       Date:  2008-07-28       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.